Exact Mass: 473.11106140000004
Exact Mass Matches: 473.11106140000004
Found 117 metabolites which its exact mass value is equals to given mass value 473.11106140000004,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
CMP-N-trimethyl-2-aminoethylphosphonate
C14H27N4O10P2+ (473.12023619999997)
This compound belongs to the family of Pyrimidine Ribonucleoside Diphosphates. These are pyrimidine ribobucleotides with diphosphate group linked to the ribose moiety.
1-(s-glutathionyl)-2,4-dinitrobenzene
C16H19N5O10S (473.08525940000004)
1-(s-glutathionyl)-2,4-dinitrobenzene, also known as Dinitrophenyl-S-glutathione or GS-DNP, is classified as a member of the Oligopeptides. Oligopeptides are organic compounds containing a sequence of between three and ten alpha-amino acids joined by peptide bonds. 1-(s-glutathionyl)-2,4-dinitrobenzene is considered to be practically insoluble (in water) and acidic
Dhurrin 6'-glucoside
C20H27NO12 (473.15331820000006)
Dhurrin 6-glucoside is found in cereals and cereal products. Dhurrin 6-glucoside is a constituent of Sorghum bicolor (sorghum)
(2,5-Dihydroxypyrrol-1-yl) 3',6'-dihydroxy-1-oxospiro[2-benzofuran-3,9'-xanthene]-5-carboxylate
C25H15NO9 (473.07467800000006)
(2,5-Dihydroxypyrrol-1-yl) 3',6'-dihydroxy-3-oxospiro[2-benzofuran-1,9'-xanthene]-4-carboxylate
C25H15NO9 (473.07467800000006)
6-Carboxyfluorescein N-succinimidyl ester
C25H15NO9 (473.07467800000006)
Enasidenib
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C137826 - Isocitrate Dehydrogenase Inhibitor > C168619 - IDH2 inhibitor L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent Enasidenib is an oral, potent, reversible, selective inhibitor of the IDH2 mutant enzymes, with IC50s of 100 and 400 nM against IDH2R140Q and IDH2R172K, respectively.
Lixivaptan
C147908 - Hormone Therapy Agent > C547 - Hormone Antagonist > C2180 - Vasopressin Antagonist
Monepantel
S-DNP-Glutathione
C16H19N5O10S (473.08525940000004)
2-Amino-5-[[(2S)-1-[N-(carboxymethyl)-2,3-dinitroanilino]-1-oxo-3-sulfanylpropan-2-yl]amino]-5-oxopentanoic acid
C16H19N5O10S (473.08525940000004)
2-Amino-5-[[(2S)-1-[N-(carboxymethyl)-2,4-dinitroanilino]-1-oxo-3-sulfanylpropan-2-yl]amino]-5-oxopentanoic acid
C16H19N5O10S (473.08525940000004)
Dhurrin 6'-glucoside
C20H27NO12 (473.15331820000006)
ON-01910
C21H24NNaO8S (473.11202640000005)
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor D000970 - Antineoplastic Agents
Pyrimido[2,1-f]purine-2,4,8(1H,3H,9H)-trione,7-[2-(ethylsulfonyl)ethyl]-6-hydroxy-1,3-dimethyl-9-(phenylmethyl)-
C21H23N5O6S (473.13689780000004)
NAN-190 hydrobromide
C23H28BrN3O3 (473.1313918000001)
D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D012702 - Serotonin Antagonists NAN-190 hydrobromide is a serotonin receptor 5-HT antagonist. NAN-190 is a selective antagonist of 5-HT1A[1][3].
(2R,3S)-2-[(1R)-1-[3,5-Bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)morpholine hydrochloride
C20H19ClF7NO2 (473.09924680000006)
5-[4-[3-chloro-4-[(3-fluorophenyl)methoxy]anilino]quinazolin-6-yl]furan-2-carbaldehyde
9-(1,1-bipheny)-4-yl-3-(4-broMophenyl)carbazole
C30H20BrN (473.07790200000005)
Methyl5-acetamido-4,7,8,9-tetra-O-acetyl-2,6-anhydro-3,5-dideoxy-D-glycero-D-galacto-non-2-enonate
C20H27NO12 (473.15331820000006)
Rosiglitazone maleate
C22H23N3O7S (473.12566480000004)
C78276 - Agent Affecting Digestive System or Metabolism > C29711 - Anti-diabetic Agent > C98241 - Thiazolidinedione Antidiabetic Agent C274 - Antineoplastic Agent > C2122 - Cell Differentiating Agent > C1934 - Differentiation Inducer D007004 - Hypoglycemic Agents Rosiglitazone maleate (BRL 49653C) is a potent and selective activator of PPARγ, with EC50s of 30 nM, 100 nM and 60 nM for PPARγ1, PPARγ2, and PPARγ, respectively, and a Kd of appr 40 nM for PPARγ; Rosiglitazone maleate is also an modulator of TRP channels, inhibits TRP melastatin 2 (TRPM2), TRPM3 and activates TRP canonical 5 (TRPC5).
(S)-1-(Diphenylphosphino)-2-[(S)-4-isopropyloxazolin-2-yl]ferrocene
C28H20FeNOP (473.06318300000004)
Pazopanib Hydrochloride
C21H24ClN7O2S (473.14006340000003)
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor > C93259 - VEGFR Tyrosine Kinase Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163953 - VEGFR-targeting Agent C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C164037 - PDGFR-targeting Agent C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163999 - cKIT-targeting Agent C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C159198 - c-KIT Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C164035 - FGFR-targeting Agent C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C155727 - FGFR Inhibitor
2-[N-(2-acetyloxyethyl)-2-chloro-4-[(2-cyano-3-nitrophenyl)diazenyl]anilino]ethyl acetate
C21H20ClN5O6 (473.11020500000006)
[[[[[1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol- 3-yl]acetyl]oxy]acetyl]oxy]acetic acid
C23H20ClNO8 (473.08773900000006)
3-Bromo-9-(1,1:3,1-terphenyl-3-yl)-9H-carbazole
C30H20BrN (473.07790200000005)
3-Bromo-9-(1,1:4,1-terphenyl-4-yl)-9H-carbazole
C30H20BrN (473.07790200000005)
(2R,3S)-2-[(1S)-1-[3,5-Bis(trifluoroMethyl)phenyl]ethoxy]-3-(4-fluorophenyl)Morpholine hydrochloride
C20H19ClF7NO2 (473.09924680000006)
(2R,3R)-2-[(1S)-1-[3,5-Bis(trifluoroMethyl)phenyl]ethoxy]-3-(4-fluorophenyl)Morpholine hydrochloride
C20H19ClF7NO2 (473.09924680000006)
4-[(2-Aminoethyl)(5-chloro-2-benzoxazolyl)amino]-2-butanone methanesulfonate
C15H24ClN3O8S2 (473.06932939999996)
N-{1-cyano-2-[5-cyano-2-(trifluoromethyl)phenoxy]-1-methylethyl}-4-[(trifluoromethyl)thio]benzamide
Monepantel
C254 - Anti-Infective Agent > C276 - Antiparasitic Agent > C250 - Antihelminthic Agent Monepantel is organic anthelmintic, and acts as a positive allosteric modulator of a nematode-specific clade of nicotinic acetylcholine receptor (nAChR) subunits.
1-[2-[bis[4-(trifluoromethyl)phenyl]methoxy]ethyl]-3,6-dihydro-2H-pyridine-5-carboxylic acid
C23H21F6NO3 (473.1425548000001)
D018377 - Neurotransmitter Agents > D014179 - Neurotransmitter Uptake Inhibitors > D058805 - GABA Uptake Inhibitors D018377 - Neurotransmitter Agents > D018682 - GABA Agents D049990 - Membrane Transport Modulators
2-Chloro-5-(3-chloro-phenyl)-6-[(4-cyano-phenyl)-(3-methyl-3H-imidazol-4-YL)-methoxymethyl]-nicotinonitrile
N-{3-[5-(6-Amino-purin-9-YL)-3,4-dihydroxy-tetrahydro-furan-2-YL]-allyl}-2,3-dihydroxy-5-nitro-benzamide
C19H19N7O8 (473.12950539999997)
Lixivaptan
C147908 - Hormone Therapy Agent > C547 - Hormone Antagonist > C2180 - Vasopressin Antagonist
Enasidenib
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C137826 - Isocitrate Dehydrogenase Inhibitor > C168619 - IDH2 inhibitor L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent Enasidenib is an oral, potent, reversible, selective inhibitor of the IDH2 mutant enzymes, with IC50s of 100 and 400 nM against IDH2R140Q and IDH2R172K, respectively.
[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-[(3S)-3,6-diamino-2,6-dioxohexyl]phosphinic acid
Glutamyl-beta-ketophosphonate-adenosine
C16H22N6O9P- (473.11858320000005)
(2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-[(E)-4-methyl-6-(3-methyl-1,4-dioxonaphthalen-2-yl)hex-4-enoyl]oxyoxane-2-carboxylate
N-(3-chlorophenyl)-2-[6,7-dimethoxy-2,4-dioxo-3-(2-oxolanylmethyl)-1-quinazolinyl]acetamide
C23H24ClN3O6 (473.13535540000004)
1-(2,1,3-benzothiadiazol-4-ylsulfonyl)-N-(6-methyl-1,3-benzothiazol-2-yl)-3-piperidinecarboxamide
C20H19N5O3S3 (473.0649984000001)
(6-Bromo-2-pyridin-4-yl-4-quinolinyl)-[4-(2-pyridinyl)-1-piperazinyl]methanone
C24H20BrN5O (473.08511300000004)
4-({[3-(4-nitrophenyl)-1-phenyl-1H-pyrazol-4-yl]methylene}amino)-5-(2-thienyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione
N-(2,3-dihydro-1,4-benzodioxin-6-ylcarbamoyl)-2-[[5-(2-methoxyanilino)-1,3,4-thiadiazol-2-yl]sulfanyl]acetamide
C20H19N5O5S2 (473.08275640000005)
1,2-dibutyryl-sn-glycero-3-phospho-(1D-myo-inositol)(1-)
A 1-phosphatidyl-1D-myo-inositol(1-) that is the conjugate base of 1,2-dibutyryl-sn-glycero-3-phospho-1D-myo-inositol, obtained by deprotonation of the phosphate OH group; major species at pH 7.3.
1-[2,5-diethoxy-4-(1-tetrazolyl)phenyl]sulfonyl-4-(4-fluorophenyl)-3,6-dihydro-2H-pyridine
C22H24FN5O4S (473.15329560000004)
N-(2,3-dimethylphenyl)-2-[[6-(1,3-dioxo-2-isoindolyl)-1,3-benzothiazol-2-yl]thio]acetamide
3-[(2-Chlorophenyl)methyl]-7-[4-[4-(trifluoromethyl)phenyl]-1-piperazinyl]triazolo[4,5-d]pyrimidine
C22H19ClF3N7 (473.13424800000007)
1-(4-bromophenyl)-2-[3-[(4-chloroanilino)methyl]-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepin-4-ium-1-yl]ethanone
1-[5-(L-tryptophanylamino)-5-deoxy-beta-D-allofuranosyluronic acid]uracil
4-bromo-N-[3-(dimethylamino)propyl]-N-[4-(4-methoxyphenyl)-2-thiazolyl]benzamide
2-[(2S,3R,6R)-3-[[(1,3-benzodioxol-5-ylamino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-[(4-chlorophenyl)methyl]acetamide
C23H24ClN3O6 (473.13535540000004)
2-[(2R,3R,6S)-3-[[(1,3-benzodioxol-5-ylamino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-[(4-chlorophenyl)methyl]acetamide
C23H24ClN3O6 (473.13535540000004)
2-[(2R,3S,6S)-3-[[(1,3-benzodioxol-5-ylamino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-[(4-chlorophenyl)methyl]acetamide
C23H24ClN3O6 (473.13535540000004)
2-[(2R,3S,6R)-3-[[(1,3-benzodioxol-5-ylamino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-[(4-chlorophenyl)methyl]acetamide
C23H24ClN3O6 (473.13535540000004)
2-[(2S,3S,6R)-3-[[(1,3-benzodioxol-5-ylamino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-[(4-chlorophenyl)methyl]acetamide
C23H24ClN3O6 (473.13535540000004)
2-[(2S,3S,6S)-3-[[(1,3-benzodioxol-5-ylamino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-[(4-chlorophenyl)methyl]acetamide
C23H24ClN3O6 (473.13535540000004)
2-[(2R,3R,6R)-3-[[(1,3-benzodioxol-5-ylamino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-[(4-chlorophenyl)methyl]acetamide
C23H24ClN3O6 (473.13535540000004)
alpha-D-Galp-(1->4)-beta-D-Galp-O(CH2)2S(CH2)2CONH2
C17H31NO12S (473.15668860000005)
A glycoside that consists of alpha-D-galactosyl-(1->4)-beta-D-galactose having a 2-(2-aminocarbonylethylthio)ethyl moiety attached to the reducing end anomeric centre.
1-[5-(D-tryptophanylamino)-5-deoxy-beta-D-allofuranosyluronic acid]uracil
2-amino-4-({1-[(carboxymethyl)-C-hydroxycarbonimidoyl]-2-{[1,3-dihydroxy-1-(2-hydroxyphenyl)propan-2-yl]sulfanyl}ethyl}-C-hydroxycarbonimidoyl)butanoic acid
C19H27N3O9S (473.14679320000005)
CMP-2-Trimethylaminoethylphosphonate
C14H27N4O10P2+ (473.12023619999997)
S-(2,4-dinitrophenyl)glutathione
C16H19N5O10S (473.08525940000004)
AD80
AD80, a multikinase inhibitor, inhibits RET, RAF,SRCand S6K, with greatly reduced mTOR activity.
CTX-0294885 (hydrochloride)
CTX-0294885 hydrochloride is a broad spectrum kinase inhibitor that can capture 235 kinases from MDA-MB-231 cells, and can capture all members of the AKT family. CTX-0294885 hydrochloride is a powerful reagent for analysis of kinome signaling networks that can be used for the research of diseases like inflammation, diabetes, and cancer[1].
MRTF/SRF-IN-1
C24H19ClF3N3O2 (473.11178200000006)
MRTF/SRF-IN-1 (example 41) is an inhibitor of both myocardin-related transcription factor and serum response factor (MRTF/SRF). MRTF/SRF-IN-1 can be used for research for preventing cancer and fibrosis[1].
(1r,2s,9r,10s,15r)-9,11,11',15-tetrahydroxy-7-methoxy-6'-methyl-3'-oxa-12-azaspiro[tetracyclo[8.3.3.0¹,¹⁰.0³,⁸]hexadecane-2,2'-tricyclo[6.3.1.0⁴,¹²]dodecane]-1'(12'),3(8),4,4',6,6',8',10',11-nonaen-13-one
[(2r,3s,4s,5r,6s)-6-{4-[(s)-cyano(hydroxy)methyl]phenoxy}-3,4,5-trihydroxyoxan-2-yl]methyl (2e)-3-(3,4-dihydroxyphenyl)prop-2-enoate
(2s)-2-[(z)-{1-[(2r)-10-acetyl-5,11,13-trihydroxy-2,12-dimethyl-3-oxo-8-oxatricyclo[7.4.0.0²,⁷]trideca-1(9),4,6,10,12-pentaen-4-yl]ethylidene}amino]pentanedioic acid
(2r,3s,4r,5r,6s)-6-{4-[(s)-cyano(hydroxy)methyl]phenoxy}-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl (2e)-3-(3,4-dihydroxyphenyl)prop-2-enoate
(2r,3s,4r,5r,6s)-6-{4-[cyano(hydroxy)methyl]phenoxy}-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl (2e)-3-(3,4-dihydroxyphenyl)prop-2-enoate
6-{4-[cyano(hydroxy)methyl]phenoxy}-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl 3-(3,4-dihydroxyphenyl)prop-2-enoate
(2s)-2-[(e)-{1-[(2r)-10-acetyl-5,11,13-trihydroxy-2,12-dimethyl-3-oxo-8-oxatricyclo[7.4.0.0²,⁷]trideca-1(9),4,6,10,12-pentaen-4-yl]ethylidene}amino]pentanedioic acid
methyl 1-[2-(2-hydroxy-4-methoxyphenyl)-2-oxoethyl]-3,4-bis(4-hydroxyphenyl)pyrrole-2-carboxylate
(2r,3r,4r,5r,6s)-2-{7,12-dihydroxy-3,13,23-triazahexacyclo[14.7.0.0²,¹⁰.0⁴,⁹.0¹¹,¹⁵.0¹⁷,²²]tricosa-1(16),2(10),4(9),5,7,11(15),12,17(22),18,20-decaen-3-yl}-6-methyloxane-3,4,5-triol
(2s)-2-{[(2r,3s,4r)-3,4-dihydroxy-6-(methoxycarbonyl)-3,4-dihydro-2h-pyran-2-yl]oxy}-2-[(2s,3s,4r,5r)-4-hydroxy-5-(4-hydroxy-2-oxopyrimidin-1-yl)-3-methoxyoxolan-2-yl]ethanimidic acid
(2r)-2-{[(2r,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-2-(4-hydroxyphenyl)acetonitrile
C20H27NO12 (473.15331820000006)
(2s)-2-({1-[(2r)-10-acetyl-11,13-dihydroxy-2,12-dimethyl-3,5-dioxo-8-oxatricyclo[7.4.0.0²,⁷]trideca-1(9),6,10,12-tetraen-4-ylidene]ethyl}amino)pentanedioic acid
2-(4-bromophenyl)-3-[2-(hydroxymethyl)-3-methoxyphenyl]-10-methyl-2-azatricyclo[6.3.1.0⁴,¹²]dodeca-1(11),3,6,8(12),9-pentaen-5-one
C26H20BrNO3 (473.0626470000001)
2-(3-bromophenyl)-3-[2-(hydroxymethyl)-3-methoxyphenyl]-10-methyl-2-azatricyclo[6.3.1.0⁴,¹²]dodeca-1(11),3,6,8(12),9-pentaen-5-one
C26H20BrNO3 (473.0626470000001)
(2r)-2-({1-[(2r)-10-acetyl-11,13-dihydroxy-2,12-dimethyl-3,5-dioxo-8-oxatricyclo[7.4.0.0²,⁷]trideca-1(9),6,10,12-tetraen-4-ylidene]ethyl}amino)pentanedioic acid
(2r)-2-{[(2s,3s,4s)-3,4-dihydroxy-6-(methoxycarbonyl)-3,4-dihydro-2h-pyran-2-yl]oxy}-2-[(2s,3s,4r,5r)-4-hydroxy-5-(4-hydroxy-2-oxopyrimidin-1-yl)-3-methoxyoxolan-2-yl]ethanimidic acid
(2r)-3-(3-chloro-4-methoxyphenyl)-2-{[(2e)-1-hydroxy-4-[(3r,4r)-4-hydroxy-3-methyl-5-phenyloxolan-2-yl]but-2-en-1-ylidene]amino}propanoic acid
C25H28ClNO6 (473.16050580000007)
2-{[3,5-dihydroxy-6-(hydroxymethyl)-4-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-2-(4-hydroxyphenyl)acetonitrile
C20H27NO12 (473.15331820000006)
(6-{4-[cyano(hydroxy)methyl]phenoxy}-3,4,5-trihydroxyoxan-2-yl)methyl 3-(3,4-dihydroxyphenyl)prop-2-enoate
(2s)-2-(4-hydroxyphenyl)-2-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-({[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-2-yl]oxy}acetonitrile
C20H27NO12 (473.15331820000006)